Levodopa Effect and Motor Function in Late Stage Parkinson's Disease.

Area of Science:

• Neurology
• Movement Disorders
• Pharmacology

Background:

• Levodopa (L-dopa) is a primary treatment for Parkinson's disease (PD).
• Its effectiveness and the prevalence of motor complications in late-stage PD remain subjects of investigation.
• Understanding these aspects is crucial for optimizing patient management.

Purpose of the Study:

• To evaluate the motor response to L-dopa in patients with advanced Parkinson's disease (PD).
• To quantify the occurrence and severity of motor fluctuations and dyskinesias in this patient group.
• To correlate clinical assessments with objective movement data.

Main Methods:

• Thirty patients with Hoehn and Yahr stages IV-V Parkinson's disease were assessed.
• A standardized L-dopa challenge test was administered to measure motor response using the Unified Parkinson's Disease Rating Scale (UPDRS) III and timed tests.
• Motor fluctuations and dyskinesias were evaluated using UPDRS IV, supplemented by 10-day monitoring with the Parkinson's Kinetigraph (PKG).

Main Results:

• Fifty percent of patients showed at least a 15% improvement in UPDRS III scores after L-dopa administration.
• Motor fluctuations were reported by 70% of participants, and 47% experienced dyskinesias.
• PKG data indicated that dyskinesias were generally mild, and many patients exhibited significant "off" time with reduced activity.

Conclusions:

• Levodopa remains effective in improving motor symptoms for a substantial proportion of late-stage Parkinson's disease patients.
• Motor fluctuations are highly prevalent, and dyskinesias affect nearly half of patients, though often with mild severity.
• Objective monitoring with PKG provides valuable insights into the real-world experience of motor complications.